"The University of Pécs Szentágothai Research Center Virological Research Group and the Austrian biotechnology company CEBINA GmbH are launching a joint COVID-19 vaccine development project, for which both the Austrian and the Hungarian research groups have the appropriate support" - announced Professor Ferenc Jakab, virologist from Pécs, head of the Coronavirus Research Action Group.
Such and similar, large-scale research projects with international visibility can be funded, among others, by the National Virology Laboratory program announced last week, the location of which is the UP Research Center and is led by dr. Jakab Ferenc.
“Serious vaccine development projects are usually carried out in collaborations, so harmonious operation between the research sites is essential. The two institutes have also been working closely together before, resulting in promising active substance tests. These can also lead to significant progress in the future treatment of patients affected by COVID-19, and in the possible pharmacological prevention of SARS-CoV-2 infections” - the professor added.
“The CEBINA team strives to apply its decades of experience in vaccine research and development to this global problem as well. Unlike vaccines that are now in the clinical trial phase, we use a more traditional vaccine technology, which is safe and affordable for mass vaccination.
Our subunit vaccine is based on vaccine antigens that are expected to induce protective immunity in current and future coronavirus epidemics” - said dr. Eszter Nagy, CEO and founder of CEBINA.
The consortium is developing a modern, third-generation coronavirus vaccine that is fundamentally different from current development approaches. The first phase of preclinical testing of the recombinant, protein-based vaccine could be carried out as early as 2021, after which the production of the prototype can also begin.